Shares of Bicycle Therapeutics Limited (NASDAQ:BCYC) have earned a consensus rating of “Buy” from the eight research firms that are presently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $21.30.

Several analysts recently weighed in on the stock. Oppenheimer reiterated a “buy” rating and issued a $27.00 price target on shares of Bicycle Therapeutics in a report on Tuesday, July 21st. Canaccord Genuity restated a “buy” rating and set a $23.50 target price on shares of Bicycle Therapeutics in a report on Tuesday, May 12th. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Bicycle Therapeutics in a report on Thursday, August 6th. Zacks Investment Research upgraded shares of Bicycle Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 6th. Finally, BidaskClub cut shares of Bicycle Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 5th.

NASDAQ:BCYC opened at $18.30 on Friday. The firm’s fifty day simple moving average is $16.70 and its 200 day simple moving average is $14.96. Bicycle Therapeutics has a twelve month low of $6.24 and a twelve month high of $20.10.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.19). The company had revenue of $1.57 million during the quarter, compared to the consensus estimate of $2.11 million. Bicycle Therapeutics had a negative net margin of 434.29{d93457022679712214ff8a8035fa266341f9634f2c93d5e609b1bbb089e8c446} and a negative return on equity of 43.74{d93457022679712214ff8a8035fa266341f9634f2c93d5e609b1bbb089e8c446}. As a group, analysts predict that Bicycle Therapeutics will post -2.38 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. UBS Group AG purchased a new position in shares of Bicycle Therapeutics in the 2nd quarter worth about $36,000. Morgan Stanley raised its position in shares of Bicycle Therapeutics by 32,450.0{d93457022679712214ff8a8035fa266341f9634f2c93d5e609b1bbb089e8c446} in the 1st quarter. Morgan Stanley now owns 3,255 shares of the company’s stock worth $44,000 after purchasing an additional 3,245 shares during the last quarter. Squarepoint Ops LLC purchased a new position in shares of Bicycle Therapeutics in the 1st quarter worth about $179,000. Advisor Group Holdings Inc. raised its position in shares of Bicycle Therapeutics by 34,000.0{d93457022679712214ff8a8035fa266341f9634f2c93d5e609b1bbb089e8c446} in the 2nd quarter. Advisor Group Holdings Inc. now owns 34,100 shares of the company’s stock worth $537,000 after purchasing an additional 34,000 shares during the last quarter. Finally, FMR LLC purchased a new position in shares of Bicycle Therapeutics in the 2nd quarter worth about $3,277,000. 33.79{d93457022679712214ff8a8035fa266341f9634f2c93d5e609b1bbb089e8c446} of the stock is owned by hedge funds and other institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

Further Reading: Cash Asset Ratio

Analyst Recommendations for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bicycle Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Source Article